Skip Navigation
  Search Menu
Find an Expert

 

Scheherazade Sadegh-Nasseri, Ph.D.

Photo of Dr. Scheherazade Sadegh-Nasseri, Ph.D.

Professor of Pathology

Research Interests: T cell tolerance; T cell activation; T cell memory survival; Molecular mechanisms in antigen processing and presentation ...read more

Background

Dr. Scheherazade Sadegh-Nasseri is a professor of pathology at the Johns Hopkins University School of Medicine. Her research focuses on molecular mechanisms in antigen processing and presentation, T cell memory survival, T cell activation, and T cell tolerance.

Dr. Sadegh-Nasseri and her lab made the notable discovery that binding of peptides to MHC class II induces different conformations, a finding that has formed the basis for how peptide-MHC class II complexes are recognized and edited by the MHC class II accessory molecules. They have maintained a leading role in understanding mechanisms in peptide binding and the role of MHC class II accessory molecules, HLA-DM and HLA-DO in peptide exchange and editing. The team also reported the first cell free reductionist antigen processing system that identifies immunodominant epitopes from protein antigens for recognition by helper T cells. This system has led to the discovery that antigen presentation for pathogens and autoantigens follow divergent paths, a finding that has significant impact in our understanding of antigen presentation to helper T cells.

Dr. Sadegh-Nasseri received her undergraduate degree from Pahlavi University in Iran and her M.Sc. in a joint program with Harvard University and Teheran University in Iran. She earned her Ph.D. from University of California at Los Angeles. She was a Cancer Research Institute Postdoctoral Scholar in Chemistry Department at Stanford University, and a Sr. Staff Fellow in Laboratory of Immunology of NIAID at NIH prior to her current department at the JHU. 

...read more

Titles

  • Professor of Pathology

Departments / Divisions

Research & Publications

Research Summary

Dr. Sadegh-Nasseri is interested in two general areas of T cell recognition. She investigates the biophysical and biochemical processes that control formation of complexes of antigenic fragments and the MHC Class II, and addresses cellular and molecular events related to T cell tolerance.   

Lab

CD4+ helper T cells of the immune system recognize peptide fragments of self or foreign antigens that are loaded on MHC-II molecules. Understanding the biochemical and molecular factors that determine which peptides of a given antigen, called “immunodominant epitopes” are selected by the immune system for representing that particular antigen is critically important. Any alterations in the quality and quantity of MHC-II antigen presentation has major implications for the induction of immunologic memory, tolerance, and disease. In fact, it has now become clear that MHC-II antigen processing and presentation plays a major role in the pathophysiology of several autoimmune disorders including MS, infectious diseases such as HIV, and several cancers, including lung cancer.

Our lab has been defining the nature of MHC-II antigen processing and how this affects CD4 T cell recognition and effector function. Among some of our past work, we have shown that having a peptide is essential for the MHC-II structure, determined the number and nature of peptide:MHC contacts to induce activation or hyporesponsiveness (anergy) in CD4T cells, and defined how a protein chaperone HLA-DM allows for selection of high-affinity peptides that can be stably presented to CD4+ T cells. Using the biochemical principles we elucidated from these early studies, we developed a reductionist cell-free MHC-II processing system that is able to identify immunodominant epitopes of a given protein antigen. This system has identified critical epitopes in proteins implicated in autoimmunity as well as protein antigens from influenza, malaria, and HIV-1.

During the past few years, we have been investigating the mechanism of another molecular chaperone, HLA-DO, in MHC-II antigen processing and its role in T cell selection and autoimmunity. Finally, we have recently began a foray into human immunology to investigate the purpose of inducible MHC-II expression on CD4+ T cells, a cell that normally is thought to exclusively respond to, but not present its own, peptides. With these studies, we aim to precisely define the critical molecular determinants of peptide antigen presentation on MHC-II molecules in both the murine and human immune systems. Our goal is ultimately to understand how alterations in peptide presentation and immunodominance can lead to human immune disease, and how to better develop vaccines for infections and cancer that promote T cell recognition of the correct antigenic epitopes.

Selected Publications

View all on Pubmed

Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. Kim A, Hartman IZ, Poore B, Boronina T, Cole RN, Song N, Ciudad MT, Caspi RR, Jaraquemada D, Sadegh-Nasseri S. Nat Commun. 2014 Nov 21;5:5369. doi: 10.1038/ncomms6369. PMID: 25413013

HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation. Poluektov YO, Kim A, Hartman IZ, Sadegh-Nasseri S. PLoS One. 2013 Aug 8;8(8):e71228. doi: 10.1371/journal.pone.0071228. eCollection 2013. PMID: 23951115

Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells. Dalai SK, Khoruzhenko S, Drake CG, Jie CC, Sadegh-Nasseri S. Immunol Cell Biol. 2011 Nov;89(8):870-81. doi: 10.1038/icb.2011.2. Epub 2011 Mar 1. PMID: 21358746

A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes. Hartman IZ, Kim A, Cotter RJ, Walter K, Dalai SK, Boronina T, Griffith W, Lanar DE, Schwenk R, Krzych U, Cole RN, Sadegh-Nasseri S. Nat Med. 2010 Nov;16(11):1333-40. doi: 10.1038/nm.2248. Epub 2010 Oct 31. PMID: 21037588

Kim AeRyon, Tatiana Boronina, Robert N. Cole, Sadegh-Nasseri S. Linker sequences added to recombinant antigens can skew immunodominant epitope selection during antigen processing. Sci Rep. 2017 Apr 19;7:46418. doi: 10.1038/srep46418. PMID: 28422163

Patents

”Method for Identifying and Validating Dominant T Helper Cell Epitopes Using an HLA-DM-Assisted Class II Binding Assay”. Inventor: Sadegh-Nasseri Scheherazade (US)
Patent # US Patent 8,916,340

Academic Affiliations & Courses

Graduate Program Affiliation

Graduate Program in Immunology

Graduate Program in Biophysics

Graduate Program in Pathobiology

Courses and Syllabi

  • Graduate Immunology (ME:250-703)
    Lectures and discussion groups

    Activities & Honors

    Memberships

    • American Association of Immunologists, AAI

    Professional Activities

    • Director, Immunology Forum Seminar Series, Mountcastle Auditorium

    Videos & Media

    Recent News Articles and Media Coverage

    Researchers tease out glitches in immune system's self-recognition, EurekAlert! (November 21, 2014)

    New antigen test speeds drug development, JH The News-Letter (November 11, 2010)

    Immune System´s Bare Essentials Used to Speedily Detect Drug Targets,  Cusabio (November 01, 2010)

    Look at immune system shows protein selectivity, Washington Examiner (December 21, 2006)

Is this you? Edit Profile